- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03415477
Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts (Deno-ABC)
January 29, 2018 updated by: GUO WEI, Peking University People's Hospital
The efficacy of traditional therapeutic approaches for aneurysmal bone cysts (ABC), such as surgery, embolization, sclerotherapy and radiotherapy, are often compromised for lesions in axial skeletons and adolescents complicated with pathological fracture.
Therefore, denosumab, a new drug that has been successfully used in giant cell tumor of bone but has seldom used in ABC, was used to treat ABC in this trial.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Patients with primary ABC treated with perioperative denosumab in the Musculoskeletal Tumor Center of Peking University People's Hospital between January 2014 and December 2016 will be reported in this trial.Approved by the Ethics Committee of Peking University People's Hospital and with the full informed consent from the patients or their families, all patients received surgery and treatment with denosumab perioperatively.
Denosumab 120 mg was given subcutaneously (abdomen wall or upper arms) every 4 weeks (Q4W), with a loading dose on both Day 8 and Day 15 of the first cycle.
Meanwhile, all patients were suggested to take 800mg oral calcium supplement every day and avoid any dental or oral surgery (tooth extraction, tooth filling, etc.).
Patients were followed once a month since the date of surgery.
On follow-up visits, patient-reported adverse reactions, X-ray image of jawbone, serum calcium, alkaline phosphatase, renal and hepatic function, hemoglobin, white blood cell, and platelet count were collected, and histological examinations, radiological examinations (such as X-ray, computed tomography (CT), magnetic resonance image (MRI) and positron emission tomography-computed tomography (PET-CT) and postoperative functional status evaluations by MSTS(Musculoskeletal tumor society) score were conducted.
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Phase 2
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
10 years to 63 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- pathologically diagnosed with primary aneurysmal bone cyst
- lesions in axial skeletons (i.e. spine, pelvis) which are difficult to reach a satisfactory surgical margin, and surgery can lead to very high incidence of complications.
- pathological fracture
- recurrence cases
Exclusion Criteria:
- metastases or multi-focal lesions
- malignancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: denosumab (Xgeva) treatment
Patients with aneurismal bone cysts received perioperative denosumab(Xgeva).
|
Denosumab (Xgeva) 120 mg was given subcutaneously (abdomen wall or upper arms) every 4 weeks (Q4W), with a loading dose on both Day 8 and Day15 of the first cycle, perioperatively.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: at least 1-year
|
the number of participats (complete response+ partial response according to RECIST 1.1)/ total participants number.
|
at least 1-year
|
local control rate
Time Frame: at least 1-year
|
CT or MR proof that the tumor relapse in the primary site by at least two radiologist.
|
at least 1-year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with abnormal laboratory values and/or adverse events that are related to the use of Denosumab(Xgeva)
Time Frame: at least 1-year
|
include patient-reported adverse reactions, X-ray image of jawbone, serum calcium, alkaline phosphatase, renal and hepatic function, hemoglobin, white blood cell, and platelet count were collected in follow-up every 3-month.
|
at least 1-year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Ghermandi R, Terzi S, Gasbarrini A, Boriani S. Denosumab: non-surgical treatment option for selective arterial embolization resistant aneurysmal bone cyst of the spine and sacrum. Case report. Eur Rev Med Pharmacol Sci. 2016 Sep;20(17):3692-5.
- Dubory A, Missenard G, Domont J, Court C. Interest of Denosumab for the Treatment of Giant-cells Tumors and Aneurysmal Bone Cysts of the Spine. About Nine Cases. Spine (Phila Pa 1976). 2016 Jun;41(11):E654-E660. doi: 10.1097/BRS.0000000000001350.
- Skubitz KM, Peltola JC, Santos ER, Cheng EY. Response of Aneurysmal Bone Cyst to Denosumab. Spine (Phila Pa 1976). 2015 Nov;40(22):E1201-4. doi: 10.1097/BRS.0000000000001027.
- Pauli C, Fuchs B, Pfirrmann C, Bridge JA, Hofer S, Bode B. Response of an aggressive periosteal aneurysmal bone cyst (ABC) of the radius to denosumab therapy. World J Surg Oncol. 2014 Jan 20;12:17. doi: 10.1186/1477-7819-12-17.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2014
Primary Completion (Actual)
December 31, 2016
Study Completion (Actual)
December 31, 2017
Study Registration Dates
First Submitted
January 10, 2018
First Submitted That Met QC Criteria
January 29, 2018
First Posted (Actual)
January 30, 2018
Study Record Updates
Last Update Posted (Actual)
January 30, 2018
Last Update Submitted That Met QC Criteria
January 29, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Denosumab-ABC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Disease
-
Steven BurtonCompletedRecurrent Oligometastatic DiseaseUnited States
-
Sohag UniversityRecruitingRecurrent WheezesEgypt
-
Mehdi YousefiCompletedRecurrent Implantation FailureIran, Islamic Republic of
-
Centre Hospitalier Universitaire, AmiensCompleted
-
Kasr El Aini HospitalUnknownRecurrent Implantation Failure
-
Dr. Kamal RagehCompleted
-
SCARM Institute, Tabriz, IranCompleted
-
Cairo UniversityCompleted
-
Tabriz University of Medical SciencesCompletedRecurrent Implantation FailureIran, Islamic Republic of
-
Shanghai First Maternity and Infant HospitalUnknownRecurrent Implantation FailureChina
Clinical Trials on Denosumab (Xgeva)
-
mAbxience Research S.L.CompletedHealthy VolunteersPoland
-
Hellenic Society for the Study of Bone MetabolismCompleted
-
European Organisation for Research and Treatment...AmgenTerminatedBone Giant Cell TumorSpain, United Kingdom, Italy, Netherlands
-
AmgenCompletedPostmenopausal OsteoporosisUnited States, Denmark, Poland, Canada
-
AmgenCompletedHealthy VolunteerUnited States
-
NYU Langone HealthCompleted
-
Borstkanker Onderzoek GroepAmgenWithdrawn
-
Massachusetts General HospitalEmory University; University of Rochester; Amgen; University Hospitals Cleveland...UnknownMultiple MyelomaUnited States
-
Swiss Group for Clinical Cancer ResearchActive, not recruitingMetastatic Breast Cancer | Bone Metastases | Metastatic Prostate CancerSwitzerland, Germany, Austria
-
Qilu Pharmaceutical Co., Ltd.Completed